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Despite the ongoing advent of more effective immunomodulators and proteasome inhibitors, multiple
myeloma (MM) remains incurable and no effective therapy is available for advanced aggressive disease.
Although allogeneic (Allo) hematopoietic cell transplantation (HCT) has a curative potential, the outcomes
remain poor because of high treatment-related mortality (TRM), mostly due to regimen-related toxicities and
graft-versus-host disease (GVHD) in case of myeloablative conditionings, high relapse rate in case of reduced-
intensity or nonmyeloablative regimens, and possibly other unknown MM-speciﬁc issues. In an attempt to
improve TRM, without compromising conditioning intensity, we prospectively explored the feasibility and
efﬁcacy of a myeloablative but reduced-toxicity conditioning regimen, consisting of ﬂudarabine and busulfan
(FluBu4; ﬂudarabine 40 mg/m2/day and busulfan 3.2 mg/kg/day i.v.  4 days) in 22 patients with high-risk or
advanced refractory MM. The majority (14 of 22, 64%) had prior autologous HCT. The median HCT-speciﬁc
comorbidity index score was 3 (range, 0 to 6), with 46% having a Karnofsky performance score < 80%. Ten
patients had unrelated donors, 3 of whom were 7/8 HLAeloci matched. GVHD prophylaxis was tacrolimus
and methotrexate in 20 (91%). Most patients had active MM at transplantation, with a partial response in 12
of 22 (46%) and stable disease in 1 of 22 (4.5%). All 22 patients tolerated the FluBu4 conditioning well, without
early toxic deaths or graft failure. Common regimen-related toxicities included mild to moderate mucositis
(18 of 22, 82%) and mild transient liver function abnormality (9 of 22, 41%). There were no grade 4 toxicities
but grade 3 mucositis occurred in 7 of 22 patients (32%). The cumulative incidence of severe, grades III and IV
acute GVHD at day 180 was 23% (95% conﬁdence interval [CI], 10% to 47%) and that of chronic GVHD was 68%
(95% CI, 46% to 88%). The cumulative incidences of TRM at 100 days, 1 year, and 3 years were 9% (95% CI, 2% to
33%), 19% (95% CI, 7% to 44%), and 29% (95% CI, 13% to 55%), respectively. Two TRMs were due to idiopathic
pneumonia syndrome and 1 was due to cirrhosis. They all had decreased pre-HCT corresponding organ
function, with HCT-speciﬁc comorbidity index scores of > 3. With a median follow-up of 58.7 (range, 39 to
82) months, the cumulative incidences of relapse at 1 and 3 years were 37% (95% CI, 20% to 61%) and 50% (95%
CI, 29% to 75%); those for 1-year and 3-year overall survival (OS) were 58% (95% CI, 40% to 83%) and 29% (95%
CI, 15% to 57%), respectively, and those for the 1-year and 3-year progression-free survivals (PFS) were 40%
(95% CI, 23% to 67%) and 15% (95% CI, 5% to 42%), respectively. In summary, the use of the myeloablative
FluBu4 conditioning Allo-HCT for high-risk MM resulted in decreased TRM, compared with that of Allo-HCT
using conventional myeloablative regimens; however, the relapse rate was high, including in those devel-
oping moderate-to-severe chronic GVHD. This suggested a less robust graft-versus-myeloma effect againstedgments on page 59.
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A. Pawarode et al. / Biol Blood Marrow Transplant 22 (2016) 54e60 55high-risk MM, thus resulting in poor PFS and OS. Nonetheless, the FluBu4 regimen may be used as a lower-
TRM platform to combine with other strategies, eg, addition of an MM-targeted agent and/or maintenance
therapy with these agents, to decrease relapse or progression in patients with high-risk MM.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION PATIENTS AND METHODS
Multiple myeloma (MM) is a common clonal plasma cell
disorder estimated to account for 24,050 new cases and
11,090 deaths in the United States in 2014 [1]. First-line
consolidative high-dose therapy and autologous (Auto) he-
matopoietic cell transplantation (HCT) have been shown to
prolong myeloma progression [2-4] and are currently
considered a standard of care [5,6]. Although new immu-
nomodulators or targeted agents are now challenging the
way we think about the disease and its treatment, MM
remains incurable. Moreover, the prognosis is extremely
poor in high-risk cases, with a median survival of 8 to
14 months after treatment [7-11].
Allogeneic (Allo) HCT has been explored in advanced MM
as a curative option through a graft-versus-myeloma (GVM)
effect [12-21]. The existence of a GVM effect was demon-
strated after the observation of complete responses (CR) after
donor lymphocyte infusion (DLI) and withdrawal of iimmu-
nomodulators in patients with MM relapsing after Allo-HCT
[16-18]. Unfortunately, conventional myeloablative condi-
tioning is associated with an unacceptably high early
treatment-related mortality (TRM) of up to 50% [12-15]. The
use of reduced-intensity regimens to improve TRM in these
advanced MMs has not improved overall outcomes, as the
relapse rate increased up to 60% [22-25]. The use of upfront
tandem reduced-intensity related donor Allo-HCT after
Auto-HCT in early-stage MM may be associated with
improved progression-free survival (PFS) over single or
tandem Auto-HCTs in high-risk MM, but it is not consistently
in standard-risk disease [26-32]. The reason for the higher
TRM and relapse in Allo-HCT for MM remains unknown, but
they have been attributed to multiple factors, including
patient age, regimen-related toxicity in case of myeloablative
conditionings, a less potent GVM effect, and possibly
other poorly understood myeloma-speciﬁc factors
[13-15,25,33,34].
The myeloablative but reduced-toxicity ﬂudarabine and
busulfan (FluBu4) conditioning regimen was shown to be
very safe and effective for acute myeloid leukemia and
myelodysplastic syndrome, with a regimen-related toxicity
of 1%, a TRM of 3%, and a PFS rate of 75% at 1 year [35]. In
an attempt to improve outcomes by decreasing TRM
without compromising conditioning intensity, we
explored the feasibility and efﬁcacy of this myeloablative
ﬂudarabineebased Allo-HCT for high-risk or advanced
MM. Based on the Consensus Criteria by the Reduced-
Intensity Conditioning Regimen Workshop, which was
convened by the Center for International Blood and
Marrow Transplant Research in 2006, myeloablative regi-
mens ablate marrow hematopoiesis, without spontaneous
autologous hematologic recovery, while nonmyeloablative
regimens, which cause minimal to moderate cytopenias,
do not require hematopoietic stem cell support. Regimens
that do not ﬁt the deﬁnition for either are classiﬁed as
reduced-intensity regimens, resulting in potentially pro-
longed cytopenias and requiring hematopoietic stem cell
support [36].Between 2008 and 2011, we conducted a prospective study using a
myeloablative FluBu4 conditioning followed by an Allo-HCT in 22 patients
withmeasurable disease, high-risk or advanced refractoryMM. The protocol
was approved by the institutional review board at the University of Michi-
gan Comprehensive Cancer Center. The diagnosis of MM and treatment
response evaluation followed the International Myeloma Working Group
Guidelines [37,38]. High-risk MM was deﬁned by (1) unfavorable conven-
tional or ﬂuorescence in situ hybridization cytogenetics for t(4;14), t(14;16),
t(14;20) and -17p, and by exclusively conventional method for -13 and hy-
podiploidy, (2) early MM relapse or progression within 12 months after an
Auto-HCT. Disease status at transplantation was required to be stable dis-
ease or better. The FluBu4 myeloablative conditioning consisted of ﬂudar-
abine 40 mg/m2/day i.v. and busulfan 3.2 mg/kg/day i.v., both for 4 days on
days -5 through day -2, where day 0 is the day of hematopoietic cell infusion.
A busulfan pharmacokinetics study was performed on samples obtained on
day -5 in all patients. Busulfan doses on day -3 and day -2 were adjusted
accordingly to target the concentration at steady state at 600 to 900 ng/mL.
Graft-versus-host disease (GVHD) prophylaxis was tacrolimus starting on
day -3 with a targeted trough blood level of 8 to 12 ng/mL and methotrexate
5 mg/kg/day i.v. on days þ1, þ3, þ6, and þ11. Tacrolimus was tapered off by
day þ180 in patients without grades II to IV acute GVHD. Donors were
matched or single locieHLA mismatched related or unrelated. Organ func-
tion requirements included serum creatinine < 2.0 mg/dL, serum total
bilirubin < 3.0 mg/dL, aspartate and alanine transaminases < 4 times upper
limit normal, left ventricular ejection fraction .4, forced expiratory volume
and functional vital capacity  40% predicted values, diffusion capacity of
the lung for carbon monoxide  40% predicted value, and Karnofsky per-
formance status  70%. Neutrophil engraftment day was deﬁned as the ﬁrst
day of the 3 consecutive days of achieving an absolute neutrophil count
(ANC)  500/uL. Platelet engraftment day was deﬁned as the ﬁrst day of 2
consecutive days of achieving platelet count  20,000/uL without trans-
fusion support. The revised National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0 was utilized to report adverse events
and toxicities [39]. Acute and chronic GVHD severity grading and classiﬁ-
cations followed the 1995 acute GVHD consensus and 2014 National Insti-
tute of Health chronic GVHD consensus, respectively [40,41].
Statistical Considerations
Overall survival (OS) and PFS were estimated from the day of trans-
plantation (day 0) and modeled using the Kaplan-Meier method. TRM, graft
failure, GVHD, and relapse were estimated using the cumulative incidence
method. The study accrued poorly after 3 years of initiation because of
competition with other clinical trials of novel targeted agents for advanced
MM.
RESULTS
Demographics
A total of 22 MM patients were evaluated and their
characteristics are summarized on Table 1. The majority
(n ¼ 14, 64%) had a prior Auto-HCT. The median HCT-speciﬁc
comorbidity index score was 3 (range, 0 to 6) and 10 patients
(46%) had a Karnofsky performance score  80%. Twelve
patients received grafts from related and 10 from unrelated
donors, 7 of which were matched at 8/8 HLA loci and 3 at 7/8
HLA loci. Disease status at transplantation included CR in 3
(14%), very good partial response in 6 (27%), partial response
in 12 (46%), and stable disease in 1 (4.5%).
Regimen-Related Toxicity, Engraftment, and TRM
All 22 patients tolerated the myeloablative FluBu4 con-
ditioning regimen well, without early toxic deaths or graft
failure. The median times to neutrophil and platelet en-
graftments were 11 days (range, 10 to 14) and 11 days (range,
Table 2
Adverse Events
Organ System National Cancer Institute
Common Terminology Criteria
for Adverse Events
Grade 1 Grade 2 Grade 3
Mucositis
Oral 5 6 7
Colitis 1
Perianal/perineal 1
Liver function abnormalities
Transaminitis 9
Hyperbilirubinemia 3 2
Elevated alkaline phosphatase 1
Infection
Pneumonia 1
CMV retinitis 1
Lips 1
Nausea/vomiting 1 1
Autoimmune thrombocytopenia 1
Urinary tract obstruction 1
Hiccups 1
Acute kidney injury 1
CMV indicates cytomegalovirus.
Data presented are n.
Table 1
Patient, Disease, and Transplantation Characteristics and Outcomes
Variable Value
No. of patients 22
Gender: male/female 14/8
Age at transplantation, median (range), yr 54 (45-70)
Follow-up time, median (range), mo 58.7 (39.5-82)
Myeloma status at transplantation
CR1 2
CR2/PR1/VGPR1 1/3/1
PR2/VGPR2/SD2 6/5/1
PR3 1
PR4 2
Prior lines of therapy, median (range) 2 (1-4)
Prior autologous transplantation
None 8 (36%)
1 10 (46%)
2 4 (18%)
Disease risk of relapse
Low 3 (14%)
Intermediate and high 19 (86%)
HCT-CI score, median (range) 3 (0-6)
Karnofsky Performance Status
>80% 12 (54%)
80% 10 (46%)
Donor
Related:unrelated 12:10
8/8:7/8 HLA match 17:5
Cell dose,  106 CD34þ cells/kg, median (range) 6.3 (4.4-10.7)
Time to engraftment, median (range), d
Neutrophil 11 (10-14)
Platelet 11 (0-15)
Regimen-related toxicities
Gastrointestinal: mucositis 19 (86%)
Grade 1-2 10 (45%)
Grade 3-4 9 (41%)
Hepatobiliary: grade 1-2 13 (59%)
Cirrhosis 1 (4.5%)
Infection: grade 1-2 3 (13%)
Pulmonary (idiopathic pneumonia
syndrome): grade 5
2 (9%)
Cumulative incidence of TRM (95% CI)
At 100 days 9% (2%-33%)
At 1 year 19% (7%-44%)
At 3 years 29% (13%-55%)
Cumulative incidence of GVHD (95% CI)
Acute GVHD at 180 days
Grade II-IV 41% (23%-65%)
Grade III-IV 23% (10%-47%)
Chronic GVHD
At 180 days 41% (23%-65%)
At 1 year 68% (46%-88%)
Cumulative incidence of relapse (95% CI)
At 100 days 14% (4%-37%)
At 1 year 37% (20%-61%)
At 3 years 50% (29%-75%)
OS (95% CI)
At 1 year 58% (40%-83%)
At 3 years 29% (15%-57%)
PFS (95% CI)
At 1 year 40% (23%-67%)
At 3 years 15% (5%-42%)
PR indicates partial response; VGPR, very good partial response; SD, stable
diseases; HCT-CI, hematopoietic cell transplantationespeciﬁc comorbidity
index.
Data presented are n (%), unless otherwise indicated.
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(Table 2) included mucositis (n ¼ 18, 82%) and transaminitis
(n ¼ 9, 41%). No grade 4 toxicities occurred with the FluBu4
regimen. Seven patients (32%) developed grade 3 oral
mucositis. There were no grade 3 abnormal liver functions
reported. The cumulative incidences of TRM at 100 days,
1 year, and 3 years were 9% (95% conﬁdence interval [CI], 2%
to 33%), 19% (95% CI, 7% to 44%), and 29% (95% CI, 13% to 55%),respectively (Figure 1A). Two TRMs were due to idiopathic
pneumonia syndrome and 1 was due to cirrhosis. These
patients had decreased pretransplantation corresponding
organ function, with HCT-speciﬁc comorbidity scores of 3 or
higher.Survival and Relapse
With a median follow-up of 58.7 months (95% CI, 39.5% to
82%), the cumulative incidences of MM progression or relapse
at 100 days, 1 year, and 3 years were 14% (95% CI, 4% to 37%),
37% (95% CI, 20% to 61%), and 50% (95% CI, 29% to 75%),
respectively (Figure 1B). The OS rates at 1 and 3 years were
58% (95% CI, 40% to 83%) and 29% (95% CI, 15% to 57%), with 1-
year and 3-year PFS rates of 40% (95% CI, 23% to 67%) and 15%
(95% CI, 5% to 42%), respectively (Figure 2A,B). The causes of
death were MM progression in 6 patients (27%), severe organ
toxicities in 3 (14%), severe chronic GVHD with/without sec-
ondary infection in 3 (14%; 2 GVHDs of gastrointestinal tract
and 1 bronchiolitis obliterans), very severe acute GVHD of
skin/liver/gastrointestinal tract in 1 HLA-DR mismatched pa-
tient (4%), and a late unknown etiology in 1 (4%).GVHD
Cumulative incidences of grades II to IV and grades III and
IV acute GVHD at day 180 were 41% (95% CI, 23% to 65%) and
23% (95% CI, 10% to 47%) (Figure 3A), respectively. Organ-
speciﬁc staging and overall grading of acute GVHD are
shown in Table 3. Most were grades I and II acute skin GVHD
(n ¼ 9, 41%) and the most common severe grades III and IV
were of the gastrointestinal system (n ¼ 5; 23%). Cumulative
incidence of chronic GVHD at 1 year was 68% (95% CI, 46% to
88%) and no events were observed beyond 1 year (Figure 3B).
The National Institutes of Health Global Severity Scores for 13
patients with chronic GVHD were mild in 2 (15%), moderate
in 5 (39%), and severe in 6 (46%). Of note, one half of patients
who experienced chronic GVHD (7 of 13, 54%) developed
concurrent or subsequent MM relapse or progression.
A majority of these (6 of 7, 86%) were of moderate to high
severity scores.
Figure 1. TRM and relapse. The actuarial 3-year cumulative incidences of TRM (A) and MM relapse or progression (B) were 29% and 50%, respectively.
Figure 3. Grade III and IV acute GVHD and chronic GVHD. The actuarial cumulative incidences of grade III and IV acute GHVD at day 180 (A) and chronic GVHD at 1
year (B) were 23% and 68%, respectively.
Figure 2. OS and PFS. The actuarial 3-year OS (A) and PFS (B) rates were 29% and 15%, respectively.
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Table 3
Staging and Grading of Acute GVHD
Organ System Acute GVHD Stage
1 2 3 4
Skin 7 2 1 1
Liver - 2 - 1
GI tract 3 - 1 4
Overall Grade
I II III IV
5 5 1 4
GI indicates gastrointestinal.
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Despite the advent of novel highly potent anti-MM
targeted agents, immunomodulators, and proteasome in-
hibitors, very few effective treatment options are available
for patients with advanced relapsed/refractory MM [42]. The
treatment outcomes of the triple regimendbortezomib,
lenalidomide, and dexamethasone, which is highly effective
for newly diagnosed MMdwere very disappointing when
used in patients with advanced relapsed/refractory MM
(prior number of regimens, 1 to 3). The reported 3-year PFS
was 10% [43]. Allo-HCT, which utilizes an alloimmune reac-
tion against MM (GVM effect), has emerged as an alternative
treatment option with possible prolonged MM control and
curative potential in these patients [12-21]. The existence of
the GVM effect was demonstrated directly in patients who
received DLI for MM relapse after Allo-HCT [16-18]. DLI was
shown to induce complete and partial response in 40% to 55%
of these patients, with accompanying acute and chronic
GVHD rates of 55% to 57% and 26% to 47%, respectively
[16-18]. The response was durable; in the largest series by
Lokhorst, the median PFS and OS were 19 and 23 months,
respectively [18].
The initial use of myeloablative conditioning resulted in
unacceptably high early TRM of up to 40% to 50%; however, a
plateau of the long-term MM progression survival curve was
demonstrated in those who survived and achieved CR after
transplantation, suggesting a cure [12-15]. The attempts to
decrease TRM by use of reduced-intensity conditionings,
especially the ﬂudarabine/melphalan regimens, were rela-
tively successful. The reported TRMwas as low as 10% to 20%
but at the expense of the MM relapse rate, which was as high
as 80% [22-25]. These ﬁndings emphasized the impact of the
intensity of the conditioning regimens in controlling MM
early after transplantation in patients with advanced re-
fractory disease [22-25].
The use of reduced-intensity Allo-HCT after Auto-HCT
(tandem Auto/Allo-HCTs) in patients with newly diagnosed
MM according to availability of matched related donors
(genetic randomization) initially showed promising out-
comes, with improved PFS and OS and without increased
TRM [26]; however, subsequent randomized controlled trials
(RCTs) enrolling either all comers [30] or only those with
high-risk disease [27,28] and the meta-analyses [29,32] of
these studies showed no deﬁnite beneﬁts. The RCTs in pa-
tients with high-risk MM from France (13 deletion or serum
beta-2-microglobulin >3 mg/dL) and Spain (achieving less
than near CR after Auto-HCT) failed to show any survival
beneﬁts of tandem Auto/Allo-HCTs, despite the increased CR
rate [27,28]. Compared with the tandem Auto-HCT controls,
there was an increase in TRM and CR; however, only a trend
toward superior late survival after 36 months in the tandem
Auto/Allo-HCT cohort was seen in a subsequentmeta-analysis [29]. A more recent RCT in all comers by the
European Society for Blood and Marrow Transplantation
revealed superior CR and PFS. However, 50% of the control
group in this study received only a single Auto-HCT [31].
Lastly, the Blood and Marrow Transplant Clinical Trials
Network has reported no beneﬁt of upfront tandem Auto/
Allo-HCTs in patients with exclusively standard-risk MM
[32].
In an attempt to further improve outcomes by decreasing
TRM without compromising conditioning intensity, we
studied a myeloablative conditioning regimen consisting
of ﬂudarabine and busulfan (FluBu4), which has been asso-
ciated with reduced regimen-related toxicity [35,44],
compared with other conventional myeloablative regimens
in patients with high-risk MM.
Our experience concurs with de Lima and Russell groups
[35,44]: the myeloablative FluBu4 regimen used in patients
with MM is safe and feasible, with a more favorable TRM,
comparable to that reported with the reduced-intensity
ﬂudarabine/melphalan regimens used in patients with MM
[22,23,45] (Table 4). The most common regimen-related
toxicities were oral mucositis and transient abnormal liver
function tests. Serious and life-threatening toxicities
occurred only in those with pre-existing organ-speciﬁc
comorbidities. The engraftments were early and there were
no cases of graft failure. The rates of acute and chronic GVHD
were similar to the reported rates for the commonly used
reduced-intensity ﬂudarabine/melphalan regimens used in
patients with MM [22,23,45] and for the FluBu4 used in pa-
tients with acute myeloid leukemia and myelodysplastic
syndrome [35,44]. However, the MM relapse/progression
rates remained universally high with both ﬂudarabine/
melphalan [22,23,45] and the FluBu4 regimen, with a 3-year
PFS of 15% in this study. Of note, one half of patients who
experienced chronic GVHD concurrently or subsequently
developed MM relapse/progression, indicating a less robust
GVM effect against high-risk MM. It is also worth noting that
theMM relapse ratewas remarkably lowwith the addition of
a proteasome inhibitor bortezomib to a reduced-intensity
ﬂudarabine/melphalan regimen in the Nishihori series [46],
emphasizing the critical role of anti-MM properties in the
conditioning in controlling MM relapse/progression. Lastly,
chronic GVHD continued to cause signiﬁcant long-term
morbidity and mortality with the use of both ﬂudarabine/
melphalan [23,45,46] and the FluBu4 conditioning regimen
in this study for MM. Three of 7 (43%) treatment-related
deaths were due to severe chronic GVHD.
Nonetheless, our 3-year PFS of 15% is favorably compa-
rable with the 3-year PFS of 10% reported from the afore-
mentioned phase 2 study of combination bortezomib,
lenalidomide, and dexamethasone in patients with advanced
relapsed/refractory MM [43]. The substitution of bortezomib
with carﬁlzomib in a similar triple regimen; however,
improved the 3-year PFS tow38%, suggesting a critical role of
carﬁlzomib or newer generation proteasome inhibitors in the
treatment of advanced MM [47].
In summary, Allo-HCT using the FluBu4 conditioning for
high-risk MM appeared to be safe with low TRM. Despite its
myeloablative property, however, the relapse/progression
rate was unacceptably high and chronic GVHD remained a
major contribution to treatment-related morbidity and
mortality. This regimen may be used as a novel low-TRM
platform for testing additional strategies, such as the addi-
tion of a MM-targeted agent with anti-GVHD property (eg,
proteasome inhibitors especially carﬁlzomib or newer
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A. Pawarode et al. / Biol Blood Marrow Transplant 22 (2016) 54e60 59agents) and/or maintenance therapy with these agents to
decrease relapse/progression in patients with high-risk MM.
A randomized phase 2 study of maintenance ixazomib, an
oral proteasome inhibitor, after Allo-HCT for high-risk MM is
under development by the Blood and Marrow Transplant
Clinical Trials Network [48].
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